The Myeloma Trial Finder lists the clinical trials that are currently recruiting in the UK. If you are thinking about joining a clinical trial you should talk to your healthcare team to find out if this is a suitable option for you.

Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone, please call the Myeloma Infoline on 0800 980 3332

Last update: 11/07/2024

There are currently 37 open trials. In 141 locations

What is a Clinical Trial?

Step 2: Choose a Trial

There are currently 37 open trials

Step 3: View Details

Trial Title:

Ide-cel CAR-T cell treatment with lenalidomide maintenance for newly diagnosed myeloma (KarMMa-9)


Ide-cel (bb2121) (CAR-T cell therapy)
Lenalidomide (Revlimid®)

Myeloma stage:

Newly Diagnosed

Trial phase:




This trial is investigating the effectiveness and tolerability of idecabtagene vicleucel (ide-cel) with lenalidomide (Revlimid®) maintenance treatment compared to lenalidomide maintenance treatment on it’s own, for people with newly diagnosed myeloma who have not had a complete response to high‑dose therapy and stem cell transplantation (HDT-SCT).

CAR-T cell treatment is a type of immunotherapy and uses the body’s own immune system to kill myeloma cells. CAR-T cells are made by taking T-cells (a type of immune cell) from the patient’s blood and genetically modifying them in a laboratory, so they are much better at finding and killing myeloma cells. The new CAR-T cells are then given back to the patient. The CAR-T cells can then find and kill the myeloma cells.

Lenalidomide is an immunomodulatory drug (IMiD) that works by affecting the body’s immune system. Maintenance treatment in myeloma is treatment given long‑term after the main treatment has finished and is intended to lengthen remission time and delay disease progression.



Queen Elizabeth Hospital, Birmingham

Who can enter the study?

Who can enter the study?:

Newly diagnosed myeloma patients who have had high-dose therapy and autologous stem cell transplantation (HDT-SCT) for myeloma. Patients must have had at least a partial response (PR) or very good partial response (VGPR) to treatment and had their stem cell transplant 80-120 days ago.

High-dose (induction) therapy before transplant must have included 4-6 cycles of therapy that included a proteosome inhibitor and immunomodulatory agent (IMiD) with or without a CD38 monoclonal antibody.

What's involved?

What's involved?:

Patients will be randomised to receive either ide-cel CAR-T treatment with lenalidomide maintainence, fludarabine (Fludara®) and cyclophosphamide or lenalidomide maintenance treatment alone.

Patients will be required to attend outpatient clinics for regular check-ups and tests.

Patients will be followed up for up to 5 years.

Clinical Information

Clinical Information
(for Medical Professionals):

A randomized, open-label, phase 3 trial to compare the efficacy and safety of idecabtagene vicleucel With lenalidomide maintenance versus lenalidomide maintenance therapy alone in adult participants with newly diagnosed multiple myeloma who have suboptimal response after autologous stem cell transplantation (KarMMa-9).

For more information, click here.


Find out more about Myeloma UK:


Do you want to talk to someone? Call our myeloma Infoline